1 | Name Of Cluster | Thane Pharma cluster |
2 | Place | Thane |
3 | District | Thane |
4 | State | Maharashtra |
5 | No of firms (by type) | 37 |
6 | No. of workers | 1700 |
7 | Turnover(Rs in Million's) | 1300million |
8 | Associations in cluster | NA |
9 | Major products | Aluminum Hydroxide Gel Magnesium Hydroxide Paste Metronidazole benzoate Chlorozoxagone Dicyclomine Hydrochloride Phenobarbitone IP Carbonil Iron Vitamin B12 ZelatinTrituarate Iron Polymaltose Nitrazebam |
10 | Specific and relevant technical institutions (R&D, Testing Lab accredited) |
NA |
11 | Major markets | Mumbai, Thane, Raigad, Pune, Tarapur Latin America, Mexico, Pakistan, Asian countries , South Africa |
12 | Major problems/prospects | Need for easy Finance to meet Revised GMP standards and increase exports. Role of Banking Sector: It has been pointed that whenever a SSI account is categorized as Non-Performing Asset (NPA), the unit is immediately threatened to be put in DRT The investment limit for plant and machinery in the small scale sector has been reduced from Rs. 3 crores to Rs. 1 croreNon-availability of Skilled manpower The Small Scale units does not pay much more attention in improving their managerial skills Burden of Taxes There are very few Small Scale units which export bulk drugs to the formulation units in abroad countries The development of pharmaceutical sector is dependent on the support of Food & Drug Administration. Technical Problems faced by the Cluster Issues relating to WHO-GMP compliance have been a relatively major area of concern for the industry as a whole. The international quality norms especially those related to exports is also a major area of concern. Low investment in R&D Small firms are finding it difficult to avail right information as regards market, finance, technical, Govt. procedures etc. Need for Common Testing Laboratory Lack of knowledge of Govt. rules and regulations |
13 | Data source and updated on | NA |